Tampa

Az itteni vizsgálatok

Miről szól a helyszín 87 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Asztma13 vizsgálat
• Tüdőrák11 vizsgálat
• Krónikus obstruktív tüdőbetegség (COPD)10 vizsgálat
• Prosztatarák7 vizsgálat
• Mielóma multiplex6 vizsgálat
• Máj- és epeúti rák5 vizsgálat
• Hasnyálmirigyrák3 vizsgálat
• Krónikus limfoid leukémia (CLL)3 vizsgálat
• Krónikus vesebetegség3 vizsgálat
• Méhtestrák3 vizsgálat
• Myasthenia gravis3 vizsgálat
• Petefészekrák3 vizsgálat
• és még 25

Fázis

• 3. fázis41 vizsgálat
• 2. fázis23 vizsgálat
• 1/2. fázis10 vizsgálat
• 1. fázis7 vizsgálat
• 2/3. fázis1 vizsgálat

Állapot

• Lezárult30 vizsgálat
• Toboroz19 vizsgálat
• Fut, nem toboroz18 vizsgálat
• Még nem toboroz10 vizsgálat
• Felfüggesztve4 vizsgálat
• Leállították3 vizsgálat
• Visszavonták3 vizsgálat

Fő szponzor

• AstraZeneca71 vizsgálat
• Alexion Pharmaceuticals, Inc.5 vizsgálat
• Acerta Pharma BV3 vizsgálat
• MedImmune LLC3 vizsgálat
• Alterome Therapeutics, Inc.1 vizsgálat
• és még 4

Futó vizsgálatok

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

  NCT07619131· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07681596· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· 2. fázis· Kinaset Therapeutics Inc· Forrás

  Contact: Kinaset investigative site

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

  NCT07192614· 1/2. fázis· AstraZeneca· Forrás

• Még nem toboroz

  LTFU for All Cell and Gene Therapy Studies

  NCT06194461· AstraZeneca· Forrás

• Toboroz

  A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  NCT07081646· 1/2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Toboroz

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

  NCT07073547· 1. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· 2. fázis· AstraZeneca· Forrás

• Toboroz

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06879041· 1. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

  NCT06835569· 1. fázis· Alterome Therapeutics, Inc.· Forrás

• Fut, nem toboroz

  A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

  NCT06749457· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD0754 in Participants With Metastatic Prostate Cancer

  NCT06267729· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· 3. fázis· AstraZeneca· Forrás

• Toboroz

  AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  NCT06137118· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Forrás

• Toboroz

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· 3. fázis· DalCor Pharmaceuticals· Forrás

  Contact: David Kallend, MBBS

• Toboroz

  AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  NCT05850234· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

  NCT05061134· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  NCT04594642· 1. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

  NCT04035486· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

  NCT03459846· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

  NCT02671435· 1/2. fázis· MedImmune LLC· Forrás

• Fut, nem toboroz

  A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

  NCT02519348· 2. fázis· MedImmune LLC· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· 3. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· 3. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· 2. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· 2. fázis· MedImmune LLC· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Prosztatarák6 toboroz
• Mielóma multiplex5 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)3 toboroz
• Máj- és epeúti rák2 toboroz
• Méhtestrák2 toboroz
• Szívelégtelenség2 toboroz
• Tüdőrák2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Amiloidózis1 toboroz
• Asztma1 toboroz
• Elhízás1 toboroz
• Follikuláris limfóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hodgkin-limfóma1 toboroz
• Koszorúér-betegség1 toboroz
• Petefészekrák1 toboroz
• Vastagbélrák1 toboroz

Lezárt vizsgálatok

• Toboroz

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

  NCT06644924· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

  NCT06675175· 1. fázis· AstraZeneca· Forrás

• Lezárult

  A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

  NCT06595238· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

  NCT06336356· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  NCT05877599· 1. fázis· AstraZeneca· Forrás

• Lezárult

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· 3. fázis· AstraZeneca· Forrás

• Lezárult

  An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

  NCT05492877· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT05573464· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

  NCT05199584· 2. fázis· Endeavor Biomedicines, Inc.· Forrás

• Lezárult

  A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

  NCT05432167· 2. fázis· AstraZeneca· Forrás

• Leállították

  Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

  NCT05218096· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· 3. fázis· AstraZeneca· Forrás

• Leállították

  Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

  NCT04999020· 2/3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  MEOI and HRQoL in CLL Patients Treated With BTKis

  NCT04938141· AstraZeneca· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

  NCT04564027· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

  NCT04249362· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Tezepelumab COPD Exacerbation Study

  NCT04039113· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Disease Registry of Patients With Mantle Cell Lymphoma

  NCT03816683· AstraZeneca· Forrás

• Lezárult

  A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

  NCT03759366· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· AstraZeneca· Forrás